We are live on
!
Find out more
KCA
KVP Capital Advisors Portfolio holdings
AUM
$134M
This Fund
S&P 500
This Quarter
Est. Return
+167.4%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.8M
AUM Growth
–
Cap. Flow
+$78.5M
Cap. Flow
% of AUM
81.13%
Top 10 Holdings %
Top 10 Hldgs %
71.43%
Holding
25
New
25
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$10.2M |
| 2 |
Praxis Precision Medicines
PRAX
|
+$7.99M |
| 3 |
Insmed
INSM
|
+$5.2M |
| 4 |
Axsome Therapeutics
AXSM
|
+$5.05M |
| 5 |
WHWK
Whitehawk Therapeutics
WHWK
|
+$4.97M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TERN
1
DELISTED
Terns Pharmaceuticals
TERN
| $17.8M | 18.36% |
+440,000
| New | +$10.2M |
|
|
2
Praxis Precision Medicines
PRAX
$8.77B
| $12.6M | 13.06% |
+42,900
| New | +$7.99M |
|
|
3
Axsome Therapeutics
AXSM
$11.7B
| $6.61M | 6.83% |
+36,200
| New | +$5.05M |
|
|
WHWK
4
Whitehawk Therapeutics
WHWK
$190M
| $5.24M | 5.41% |
+2,165,997
| New | +$4.97M |
|
5
Trevi Therapeutics
TRVI
$2.35B
| $5.18M | 5.35% |
+414,000
| New | +$4.78M |
|
|
6
Insmed
INSM
$23.7B
| $4.96M | 5.12% |
+28,497
| New | +$5.2M |
|
7
Protagonist Therapeutics
PTGX
$8.35B
| $4.63M | 4.78% |
+53,000
| New | +$4.34M |
|
8
Disc Medicine
IRON
$2.9B
| $4.63M | 4.78% |
+58,250
| New | +$4.92M |
|
|
MBX
9
MBX Biosciences
MBX
$2.86B
| $3.83M | 3.96% |
+121,524
| New | +$2.95M |
|
10
Savara
SVRA
$1.18B
| $3.65M | 3.77% |
+605,280
| New | +$2.96M |
|
11
Travere Therapeutics
TVTX
$5.23B
| $3.48M | 3.59% |
+91,000
| New | +$2.96M |
|
12
Edgewise Therapeutics
EWTX
$4.44B
| $3.3M | 3.41% |
+133,000
| New | +$2.67M |
|
13
Jazz Pharmaceuticals
JAZZ
$14.9B
| $2.98M | 3.07% |
+17,500
| New | +$2.68M |
|
|
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
| $2.76M | 2.86% |
+59,700
| New | +$3.27M |
|
15
United Therapeutics
UTHR
$22.7B
| $2.31M | 2.39% |
+4,750
| New | +$2.21M |
|
16
Achieve Life Sciences
ACHV
$626M
| $2.3M | 2.37% |
+462,355
| New | +$2.02M |
|
17
Revolution Medicines
RVMD
$39.1B
| $2.19M | 2.26% |
+27,500
| New | +$1.8M |
|
18
Scholar Rock
SRRK
$6.55B
| $1.98M | 2.05% |
+45,000
| New | +$1.69M |
|
19
Vera Therapeutics
VERA
$2.98B
| $1.66M | 1.71% |
+32,700
| New | +$1.16M |
|
20
Immix Biopharma
IMMX
$749M
| $1.21M | 1.24% |
+230,423
| New | +$948K |
|
21
Nektar Therapeutics
NKTR
$2.31B
| $1.14M | 1.17% |
+26,900
| New | +$1.51M |
|
22
Cabaletta Bio
CABA
$452M
| $1.11M | 1.14% |
+505,431
| New | +$1.25M |
|
23
Fulcrum Therapeutics
FULC
$236M
| $566K | 0.58% |
+50,000
| New | +$509K |
|
24
Celcuity
CELC
$5.06B
| $399K | 0.41% |
+4,000
| New | +$329K |
|
25
VYNE Therapeutics
VYNE
$22M
| $290K | 0.3% |
+500,551
| New | +$201K |
|
Similar funds
RA
BWM
LEP
RLWM
PTFIS
SWM
SA
HCA